@JCanNuSH says Lilly held an investor call for EASD 2026 with no archived audio, and posts a slide with added Phase 3 details on EloraTZP.
Recap by typeshit. Post by @JCanNuSH on X.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
@itsjakesjourney says Wegovy shut off his desire for alcohol. One person's account, but it lines up with growing research interest in GLP-1s for addiction.
The OCTANE study of 194 adults, presented at EASD 2026, found an average 4.1% drop over three months on oral semaglutide. Doctors call it early, unreviewed evidence.
Loading…